Read by QxMD icon Read

III stage colon cancer

Javier Rodriguez, Silvestre Vicent, Ana Chopitea, Mariano Ponz-Sarvise
Although molecular subtype-based stratification and genomic signatures of increasing complexity are becoming a new strategy to guide therapeutic decisions in stage II/III colon cancer, several prognostic factors that can be easily obtained from FFPE specimens should be considered in order to create combined models that better define individual patients needs.
April 20, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Minjung Lee, Eric J Feuer, Jason P Fine
Regression methodology has been well developed for competing risks data with continuous event times, both for the cause-specific hazard and cumulative incidence functions. However, in many applications, including those from the Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute, the event times may be observed discretely. Naive application of continuous time regression methods to such data is not appropriate. We propose maximum likelihood inferences for estimation of model parameters for the discrete time cause-specific hazard functions, develop predictions for the associated cumulative incidence functions, and derive consistent variance estimators for the predicted cumulative incidence functions...
April 17, 2018: Biometrics
Sung Il Kang, Duck-Woo Kim, Eun Shin, Myung Jo Kim, Il Tae Son, Heung-Kwon Oh, Sung-Bum Kang
BACKGROUND: There are limited reports on peri-ileal lymph node metastasis in patients with right-sided colon cancer, and little is known about their clinical significance. OBJECTIVE: This study aimed to examine the role of tumor location in the prevalence and clinical significance of peri-ileal lymph node metastasis in patients with right-sided colon cancer. DESIGN: This is a retrospective study from a prospective cohort database. SETTINGS: The study was conducted at a tertiary referral hospital...
April 16, 2018: Diseases of the Colon and Rectum
Sandra Santasusagna, Isabel Moreno, Alfons Navarro, Joan J Castellano, Francisco Martinez, Raquel Hernández, Carmen Muñoz, Mariano Monzo
BACKGROUND: The analysis of exosomes in blood obtained from the tumor-draining mesenteric vein (MV) can identify tumor biomarkers before they reach target organs and form the premetastatic niche where circulating tumor cells can anchor. Our group has recently shown that microRNAs in plasma from the MV-but not the peripheral vein (PV)-have been related to liver metastases in colon cancer (CC) patients. Here we examine the exosomal protein cargo in plasma from the MV and paired PV in 31 CC patients...
April 13, 2018: Translational Oncology
Hendrik Bläker, Elizabeth Alwers, Alexander Arnold, Esther Herpel, Katrin E Tagscherer, Wilfried Roth, Lina Jansen, Viola Walter, Matthias Kloor, Jenny Chang-Claude, Hermann Brenner, Michael Hoffmeister
BACKGROUND & AIMS: Colorectal tumors with mutations in BRAF and microsatellite stability (MSS) have been associated with adverse outcomes of patients. Combined tests for microsatellite instability (MSI-H) and BRAF mutations might therefore be used in risk assessment, particularly for patients with stage II tumors. We investigate the stage-specific prognostic value of combined testing for MSI-H and BRAF for patients with colorectal cancer (CRC). METHODS: We performed a retrospective analysis of colorectal tumor samples collected from 1995 patients at 22 hospitals in Germany, between 2003 and 2010...
April 13, 2018: Clinical Gastroenterology and Hepatology
Dai Shida, Hiroki Ochiai, Shunsuke Tsukamoto, Yukihide Kanemitsu
BACKGROUND: Non-inferiority of the laparoscopic approach for stage II/III colon cancer has not been clearly established. This study aimed to evaluate the long-term outcomes of laparoscopic versus open D3 surgery. METHODS: Subjects were 1230 consecutive patients with stage II/III colon cancer, who were referred to the National Cancer Center Hospital from 2004 to 2013. Open surgery was performed in 821 (67%) patients, and laparoscopic surgery was performed in 409 (33%)...
April 5, 2018: European Journal of Surgical Oncology
Tomokazu Tokoro, Keishi Nakamura, Atsushi Hirose, Shinichi Nakanuma, Kohichi Okamoto, Jun Kinoshita, Isamu Makino, Hironori Hayashi, Katsunobu Oyama, Tomoharu Miyashita, Hidehiro Tajima, Hiroyuki Takamura, Itasu Ninomiya, Sachio Fushida, Tetsuo Ohta
The patient was a 57-year-old woman. Preclinical examination of malignant lymphoma revealed 0-I sp type of early rectal cancer in the upper rectum, 20 cm from the anal margin. Endoscopic mucosal resection was performed and positive deep margins were pathologically diagnosed. Additional intestinal resection with lymph node dissection was deemed necessary, but ABVD therapy was initiated because the clinical stage of the malignant lymphoma was Stage III b or higher. Two months after detecting elevated CEA, S8 liver metastasis was pointed out, and examination of weakness of the right upper limb revealed nodular, multifocal brain metastasis...
March 2018: Gan to Kagaku Ryoho. Cancer & Chemotherapy
Marina Baretti, Lorenza Rimassa, Nicola Personeni, Laura Giordano, Maria Chiara Tronconi, Tiziana Pressiani, Silvia Bozzarelli, Armando Santoro
BACKGROUND: Comorbidity has a detrimental effect on cancer survival, however, it is difficult to disentangle its direct effect from its influence on treatment choice. In this study we assessed the effect of comorbidity on survival in patients who received standard treatment for resected stage II and III colorectal cancer (CRC). PATIENTS AND METHODS: In total, 230 CRC patients, 68 rectal (29.6%) and 162 colon cancer (70.4%) treated with surgical resection and neoadjuvant/adjuvant chemotherapy from December 2002 to December 2009 at Humanitas Cancer Center were retrospectively reviewed...
March 21, 2018: Clinical Colorectal Cancer
Jeffery C Ward, Laura A Levit, Ray D Page, John E Hennessy, John V Cox, Deborah Y Kamin, Suanna S Bruinooge, Ya-Chen Tina Shih, Blase N Polite
INTRODUCTION: This analysis evaluates the impact of bundling drug costs into a hypothetic bundled payment. METHODS: An economic model was created for patient vignettes from: advanced-stage III colon cancer and metastatic non-small-cell lung cancer. First quarter 2016 Medicare reimbursement rates were used to calculate the average fee-for-service (FFS) reimbursement for these vignettes. The probabilistic risk faced by practices was captured by the type of patients seen in practices and randomly assigned in a Monte Carlo simulation on the basis of the given distribution of patient types within each cancer...
April 12, 2018: Journal of Oncology Practice
Tsuyoshi Konishi, Yoshifumi Shimada, Lik Hang Lee, Marcela S Cavalcanti, Meier Hsu, Jesse Joshua Smith, Garrett M Nash, Larissa K Temple, José G Guillem, Philip B Paty, Julio Garcia-Aguilar, Efsevia Vakiani, Mithat Gonen, Jinru Shia, Martin R Weiser
This study aimed to compare common histologic markers at the invasive front of colon adenocarcinoma in terms of prognostic accuracy and interobserver agreement. Consecutive patients who underwent curative resection for stages I to III colon adenocarcinoma at a single institution in 2007 to 2014 were identified. Poorly differentiated clusters (PDCs), tumor budding, perineural invasion, desmoplastic reaction, and Crohn-like lymphoid reaction at the invasive front, as well as the World Health Organization (WHO) grade of the entire tumor, were analyzed...
April 5, 2018: American Journal of Surgical Pathology
Thierry André, Dewi Vernerey, Laurent Mineur, Jaafar Bennouna, Jérôme Desrame, Roger Faroux, Serge Fratte, Marine Hug de Larauze, Sophie Paget-Bailly, Benoist Chibaudel, Jeremie Bez, Jérôme Dauba, Christophe Louvet, Céline Lepere, Olivier Dupuis, Yves Becouarn, May Mabro, Joëlle Egreteau, Olivier Bouche, Gaël Deplanque, Marc Ychou, Marie Pierre Galais, François Ghiringhelli, Louis Marie Dourthe, Jean-Baptiste Bachet, Ahmed Khalil, Franck Bonnetain, Aimery de Gramont, Julien Taieb
Purpose Reduction of adjuvant treatment duration may decrease toxicities without loss of efficacy in stage III colon cancer. This could offer clear advantages to patients and health care providers. Methods In International Duration Evaluation of Adjuvant Chemotherapy (IDEA) France, as part of the IDEA international collaboration, patient with colon cancer patients were randomly assigned to 3 and 6 months of modified FOLFOX6 (mFOLFOX6: infusional fluorouracil, leucovorin, and oxaliplatin) or capecitabine plus oxaliplatin (CAPOX) by physician choice...
April 5, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Alberto Sobrero, Sara Lonardi, Gerardo Rosati, Maria Di Bartolomeo, Monica Ronzoni, Nicoletta Pella, Mario Scartozzi, Maria Banzi, Maria Giulia Zampino, Felice Pasini, Paolo Marchetti, Maurizio Cantore, Alberto Zaniboni, Lorenza Rimassa, Libero Ciuffreda, Daris Ferrari, Vittorina Zagonel, Evaristo Maiello, Sandro Barni, Eliana Rulli, Roberto Labianca
Purpose Given the cumulative neurotoxicity associated with oxaliplatin, a shorter duration of adjuvant therapy, if equally efficacious, would be advantageous for patients and health-care systems. Methods The Three or Six Colon Adjuvant trial is an open-label, phase III, multicenter, noninferiority trial randomizing patients with high-risk stage II or stage III colon cancer to receive 3 months or 6 months of FOLFOX (fluorouracil, leucovorin, and oxaliplatin) or CAPOX (capecitabine plus oxaliplatin). Primary end-point is relapse-free survival...
April 5, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Makoto Takahashi, Hiroaki Niitsu, Kazuhiro Sakamoto, Takao Hinoi, Minoru Hattori, Michitoshi Goto, Hiroyuki Bando, Shoichi Hazama, Kiyoshi Maeda, Kenji Okita, Hisanaga Horie, Masahiko Watanabe
INTRODUCTION: In surgery for elderly patients with colorectal cancer, it is unclear whether radical lymph node (LN) dissection safely offers a survival benefit. The aim of the study was to evaluate the impact of the LN yield in elderly patients undergoing surgery for colorectal cancer. METHODS: The subjects were selected from a surgical database of 2065 patients aged ≥80 years old who underwent surgery for colorectal cancer at 41 hospitals in Japan between 2003 and 2007...
March 30, 2018: Asian Journal of Endoscopic Surgery
Axel Grothey, Alberto F Sobrero, Anthony F Shields, Takayuki Yoshino, James Paul, Julien Taieb, John Souglakos, Qian Shi, Rachel Kerr, Roberto Labianca, Jeffrey A Meyerhardt, Dewi Vernerey, Takeharu Yamanaka, Ioannis Boukovinas, Jeffrey P Meyers, Lindsay A Renfro, Donna Niedzwiecki, Toshiaki Watanabe, Valter Torri, Mark Saunders, Daniel J Sargent, Thierry Andre, Timothy Iveson
BACKGROUND: Since 2004, a regimen of 6 months of treatment with oxaliplatin plus a fluoropyrimidine has been standard adjuvant therapy in patients with stage III colon cancer. However, since oxaliplatin is associated with cumulative neurotoxicity, a shorter duration of therapy could spare toxic effects and health expenditures. METHODS: We performed a prospective, preplanned, pooled analysis of six randomized, phase 3 trials that were conducted concurrently to evaluate the noninferiority of adjuvant therapy with either FOLFOX (fluorouracil, leucovorin, and oxaliplatin) or CAPOX (capecitabine and oxaliplatin) administered for 3 months, as compared with 6 months...
March 29, 2018: New England Journal of Medicine
Robert R J Coebergh van den Braak, Anieta M Sieuwerts, Zarina S Lalmahomed, Marcel Smid, Saskia M Wilting, Sandra I Bril, Shanshan Xiang, Michelle van der Vlugt-Daane, Vanja de Weerd, Anne van Galen, Katharina Biermann, J Han J M van Krieken, Wigard P Kloosterman, John A Foekens, John W M Martens, Jan N M IJzermans
The identification of patients with high-risk stage II colon cancer who may benefit from adjuvant therapy may allow the clinical approach to be tailored for these patients based on an understanding of tumour biology. MicroRNAs have been proposed as markers of the prognosis or treatment response in colorectal cancer. Recently, a 2-microRNA signature (let-7i and miR-10b) was proposed to identify colorectal cancer patients at risk of developing distant metastasis. We assessed the prognostic value of this signature and additional candidate microRNAs in an independent, clinically well-defined, prospectively collected cohort of primary colon cancer patients including stage I-II colon cancer without and stage III colon cancer with adjuvant treatment...
March 27, 2018: Scientific Reports
Karen J Ortiz-Ortiz, Guillermo Tortolero-Luna, Ruth Ríos-Motta, Alejandro Veintidós-Feliú, Robert Hunter-Mellado, Carlos R Torres-Cintrón, Tonatiuh Suárez-Ramos, Priscilla Magno
OBJECTIVE: This study aims to examine factors associated with the use of adjuvant chemotherapy and the use of oxaliplatin after curative resection in stage III colon cancer patients and assesses the effect of their use in three-year survival. METHODS: This retrospective cohort study was conducted using Puerto Rico Central Cancer Registry-Health Insurance Linkage Database. The study cohort consisted of stage III colon cancer patients with a curative surgery in the period 2008-2012...
2018: PloS One
Blase N Polite, Toni M Cipriano-Steffens, Fay J Hlubocky, Pascal Jean-Pierre, Ying Cheng, Katherine C Brewer, Garth H Rauscher, George A Fitchett
BACKGROUND: This study explores whether externalizing religious and spiritual beliefs is associated with advanced-stage colon cancer at initial oncology presentation and whether this association is stronger for blacks than for whites. METHODS: Patients who had newly diagnosed, invasive colon cancer were recruited at 9 sites in the Chicago metropolitan area. Eligible patients were non-Hispanic white or black, ages 30 to 79 years, and diagnosed with a primary invasive colon cancer...
March 26, 2018: Cancer
Philip D Dunne, Helen G Coleman, Peter Bankhead, Matthew Alderdice, Ronan T Gray, Stephen McQuaid, Victoria Bingham, Maurice B Loughrey, Jacqueline A James, Amy M B McCorry, Alan Gilmore, Caitriona Holohan, Dirk Klingbiel, Sabine Tejpar, Patrick G Johnston, Darragh G McArt, Federica Di Nicolantonio, Daniel B Longley, Mark Lawler
Purpose: BRAF mutation occurs in 8-15% of colon cancers (CC), and is associated with poor prognosis in metastatic disease. Compared to wild-type BRAF (BRAFWT) disease, stage II/III CC patients with BRAF mutant (BRAFMT) tumors have shorter overall survival after relapse; however, time-to-relapse is not significantly different. The aim of this investigation was to identify, and validate, novel predictors of relapse of stage II/III BRAFMT CC. Experimental design: We used gene expression data from a cohort of 460 patients (GSE39582) to perform a supervised classification analysis based on risk-of-relapse within BRAFMT stage II/III CC, to identify transcriptomic biomarkers associated with prognosis within this genotype...
March 2, 2018: Oncotarget
Nina C A Vermeer, Yvette H M Claassen, Marloes G M Derks, Lene H Iversen, Elizabeth van Eycken, Marianne G Guren, Pawel Mroczkowski, Anna Martling, Robert Johansson, Tamara Vandendael, Arne Wibe, Bjorn Moller, Hans Lippert, Johanneke E A Portielje, Gerrit Jan Liefers, Koen C M J Peeters, Cornelis J H van de Velde, Esther Bastiaannet
BACKGROUND: Colon cancer in older patients represents a major public health issue. As older patients are hardly included in clinical trials, the optimal treatment of these patients remains unclear. The present international EURECCA comparison explores possible associations between treatment and survival outcomes in elderly colon cancer patients. SUBJECTS, MATERIALS, AND METHODS: National data from Belgium, Denmark, The Netherlands, Norway, and Sweden were obtained, as well as a multicenter surgery cohort from Germany...
March 22, 2018: Oncologist
Virginia Sun, Tracy E Crane, Samantha D Slack, Angela Yung, Sarah Wright, Stephen Sentovich, Kurt Melstrom, Marwan Fakih, Robert S Krouse, Cynthia A Thomson
PURPOSE: Bowel dysfunction is a common, persistent long-term effect of treatment for rectal cancer survivors. Survivors often use dietary modifications to maintain bowel control. There are few evidence-based interventions to guide survivors on appropriate diet modifications for bowel symptom management. The purpose of this paper is to describe the development and design of the Altering Intake, Managing Symptoms (AIMS) intervention to support bowel dysfunction management in rectal cancer survivors...
March 19, 2018: Contemporary Clinical Trials
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"